The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...

J&J presented the new analysis from three Phase III trials of Caplyta in MDD.

EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs Now commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to ...

New TMS biomarkers combined with machine learning accurately classified major depressive disorder. Learn more about this ...

Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with ...